Drug Profile
VM 902
Alternative Names: VM 902ALatest Information Update: 30 Nov 2017
Price :
$50
*
At a glance
- Originator VM Discovery
- Developer Purdue Pharma
- Class Small molecules
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 22 Nov 2017 Purdue Pharma terminates phase II trial in Pain in USA (NCT02847702)
- 25 Nov 2016 Purdue Pharma suspends enrolment in its phase II trial for Pain in USA (NCT02847702)
- 01 Aug 2016 Phase-II clinical trials in Pain in USA (PO) (NCT02847702)